<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39316345</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2199-9031</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of health economics and management</Title><ISOAbbreviation>Int J Health Econ Manag</ISOAbbreviation></Journal><ArticleTitle>Vaccination strategies for different contact patterns: weighing epidemiological against economic outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10754-024-09384-1</ELocationID><Abstract><AbstractText>The aim of this paper is to shed light on the economic and epidemiological trade-offs that emerge when choosing between different vaccination strategies. For that purpose we employ a setting with three age groups that differ with respect to their fatality rates. The model also accounts for heterogeneity in the transmission rates between and within these age groups. We compare the results for two different contact patterns, in terms of the total number of deceased, the total number of infected, the peak infection rate and the economic gains from different vaccination strategies. We find that fatalities are minimized by first vaccinating the elderly, except when vaccination is slow and the general transmission rate is relatively low. In this case deaths are minimized by first vaccinating the group that is mainly responsible for spreading of the virus. With regard to the other outcome variables it is best to vaccinate the group that drives the pandemic first. A trade-off may therefore emerge between reducing fatalities on the one hand and lowering the number of infected as well as maximizing the economic gains from vaccinations on the other hand.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forslid</LastName><ForeName>Rikard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Economics, Stockholm University, and CEPR, Stockholm, Sweden. rikard.forslid@ne.su.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzing</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0691-421X</Identifier><AffiliationInfo><Affiliation>School of Business, Örebro University, Örebro, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20-0257</GrantID><Agency>Jan Wallanders och Tom Hedelius Stiftelse samt Tore Browaldhs Stiftelse</Agency><Country /></Grant><Grant><GrantID>2020-02554</GrantID><Agency>Vetenskapsrådet</Agency><Country /></Grant><Grant><GrantID>P19-0031</GrantID><Agency>Vetenskapsrådet</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Health Econ Manag</MedlineTA><NlmUniqueID>101674352</NlmUniqueID><ISSNLinking>2199-9031</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pandemics</Keyword><Keyword MajorTopicYN="N">SIR-model</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316345</ArticleId><ArticleId IdType="doi">10.1007/s10754-024-09384-1</ArticleId><ArticleId IdType="pii">10.1007/s10754-024-09384-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Babus, A., Das, S., &amp; Lee, S. (2020). The optimal allocation of Covid-19 vaccines. CEPR Covid Economics, 44, 47–71.</Citation></Reference><Reference><Citation>Bartsch, S. M., O’Shea, K. J., Ferguson, M. C., Bottazzi, M. E., Wedlock, P. T., Strych, U., McKinnell, J. A., Siegmund, S. S., Cox, S. N., Hotez, P. J., &amp; Lee, B. Y. (2020). Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. American Journal of Preventive Medicine, 59(4), 493–503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2020.06.011</ArticleId><ArticleId IdType="pubmed">32778354</ArticleId><ArticleId IdType="pmc">7361120</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton, T., Ball, F., &amp; Trapman, P. (2020). A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science, 369, 846–849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6810</ArticleId><ArticleId IdType="pubmed">32576668</ArticleId><ArticleId IdType="pmc">7331793</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekmann, O., Heesterbeek, J. A. P., &amp; Metz, J. A. J. (1990). On the definition and the computation of the basic reproduction number [Formula: see text] in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology, 28(4), 365–382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00178324</ArticleId><ArticleId IdType="pubmed">2117040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimma, A., Munday, J.D., Wong, K.L.M., Coletti, P., van Zandvoort, K., &amp; Prem, K. (2022). CMMID COVIC-19 working group, P. Klepac, G.J. Rubin, S. Funk, W.J. Edmunds, and C.I. Jarvis, "Changes in social contacts in England during the COVID-19 pandemic between March 2020 and March 2021 as measured by the CoMix survey: A repeated cross-sectional study", PLOS Medicine: published March 1 2022, https://doi.org/10.1371/journal.pmed.1003907 .</Citation></Reference><Reference><Citation>Gollier, C., (2021). The welfare cost of vaccine misallocation, delays and nationalism, forthcoming in the Journal of Benefit-Cost Analysis, prepublished in CEPR Covid Economics 74, 1-24.</Citation></Reference><Reference><Citation>Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., &amp; Pollard, A. J. (2020). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(20)30773-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30773-8</ArticleId><ArticleId IdType="pubmed">33125914</ArticleId><ArticleId IdType="pmc">7837315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermack, W.O., &amp; McKendrick, A.G. (1927). A contribution to the mathematical theory of epidemics. In Proceedings of the Royal Society A. Mathematical, Physical and Engineering Sciences 115 (772), 700–721.</Citation></Reference><Reference><Citation>Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., &amp; Meyerowitz-Katz, G. (2020). Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European Journal of Epidemiology, 35, 1123–1138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-020-00698-1</ArticleId><ArticleId IdType="pubmed">33289900</ArticleId><ArticleId IdType="pmc">7721859</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyten, J., Tubeuf, S., &amp; Kessels, R. (2020). Who should get it first? Public preferences for distributing a COVID-19 vaccine. CEPR Covid Economics, 57, 1–19.</Citation></Reference><Reference><Citation>Matrajt, L., Eaton, J., Leung, T., &amp; Brown, E.R. (2020). Vaccine optimization for COVID-19, who to vaccinate first?, medRxiv preprint https://doi.org/10.1101/2020.08.14.20175257 .</Citation></Reference><Reference><Citation>Moore, S., Hill, E.M., Dyson, L., Tildesley, M.J., &amp; Keeling, M.J. (2020). Modelling optimal vaccination strategy for SARS-CoV-2 in the UK, medRxiv preprint https://doi.org/10.1101/2020.09.22.20194183 .</Citation></Reference><Reference><Citation>Roope, L. S. J., Buckell, J., Becker, F., Candio, P., Violato, M., Sindelar, J. L., Barnett, A., Duch, R., &amp; Clarke, P. M. (2020). How should a safe and effective COVID-19 vaccine be allocated? Health economists need to be ready to take the baton. PharmacoEconomics-Open, 4(4), 557–561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41669-020-00228-5</ArticleId><ArticleId IdType="pubmed">32880878</ArticleId><ArticleId IdType="pmc">7471481</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellodi, N., &amp; Weiss, J. (2021). Optimal vaccine policies: Spillovers and incentives. CEPR Covid Economics, 65, 1–46.</Citation></Reference><Reference><Citation>Verelst, F., Hermans, L., Vercruysse, S., Gimma, A., Coletti, P., Backer, J. A., Wong, K. L. M., Wambua, J., van Zandvoort, K., Willem, L., Bogaardt, L., Faes, C., Jarvis, C. I., Wallinga, J., Edmunds, W. J., Beutels, P., &amp; Hens, N. (2021). SOCRATES-CoMix: A platform for timely and open-source contact mixing data during and in between COVID-19 surges and interventions in over 20 European countries. BMC Medicine, 19(1), 254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02133-y</ArticleId><ArticleId IdType="pubmed">34583683</ArticleId><ArticleId IdType="pmc">8478607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallinga, J., Teunis, P., &amp; Kretzschmar, M. (2006). Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. American Journal of Epidemiology, 164(10), 936–944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwj317</ArticleId><ArticleId IdType="pubmed">16968863</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>